Nov 11, 2020 / 04:00PM GMT
Tiago Felipe Fauth - Crédit Suisse AG - Research Division - Research Analyst
Welcome, everyone, to the Annual Crédit Suisse Healthcare Conference. We're joined today by Anna Protopapas, CEO of Mersana Therapeutics. And she's going to give us a presentation on all the recent developments for Mersana. You can take it away, Anna.
Anna Protopapas - Mersana Therapeutics, Inc. - President, CEO & Director
Thank you, Tiago, and thank you for having us today and for the opportunity to tell you more about Mersana and why we're so excited about the potential of our current clinical programs and robust pipeline of ADC candidates. Before I start, I do want to remind you that I will be making forward-looking statements.
Mersana was founded on the vision that innovative new ADC platforms that address the limitations of the first-generation approaches could lead to therapies that could significantly improve outcomes for cancer patients in need. These platforms are: proprietary DolaLock payload with controlled bystander effect; our
Mersana Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers